Clinical Trial Update: Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension [Phase 3]

View source ↗

Summary

Phase 3 study evaluating LCZ696 (sacubitril/valsartan) alone and with amlodipine for hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Amlodipine (amlodipine)
• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypertension | Phase 3 | Status: WITHDRAWN